Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gastrointestinal stromal tumors.

C D Blanke1, B L Eisenberg, M C Heinrich

  • 1Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University and Portland Veterans Affairs Medical Center, MC OP28, 3181 S.W. Sam Jackson Park Road, Portland, OR 97201, USA. blankec@ohsu.edu

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary

Gastrointestinal stromal tumors (GISTs) are resistant to traditional treatments. A novel tyrosine kinase inhibitor, STI571, shows significant efficacy in advanced GIST patients, offering a new targeted therapy approach.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DART (NCI/SWOG S1609): comprehensive final results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Novel trial designs for patients with gastrointestinal stromal tumor.

ESMO open·2024
Same author

Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Tyrosine kinase inhibitors significantly improved survival outcomes in patients with metastatic gastrointestinal stromal tumour: a multi-institutional cohort study.

Current oncology (Toronto, Ont.)·2020
Same author

Translational insights into gastrointestinal stromal tumor and current clinical advances.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastroenterology

Background:

  • Gastrointestinal stromal tumors (GISTs) are distinct mesenchymal neoplasms.
  • Complete surgical resection is the primary therapy but has a high recurrence rate (~90%).
  • GISTs exhibit resistance to conventional chemotherapy and radiotherapy.

Purpose of the Study:

  • To evaluate the efficacy of STI571, a novel tyrosine kinase inhibitor, in treating advanced GISTs.
  • To assess the clinical activity of STI571 as a systemic treatment for GISTs.

Main Methods:

  • Treatment of advanced GIST patients with STI571.
  • Analysis of remission and tumor control rates.
  • Correlation of response rates with tumor mutational status.

Related Experiment Videos

Main Results:

  • STI571 achieved remission rates approaching 60% and overall tumor control in 85% of advanced GIST patients.
  • Specific patient groups, identified by tumor mutational status, showed response rates as high as 80%.
  • STI571 is the only systemic treatment to date demonstrating meaningful clinical activity for GISTs.

Conclusions:

  • STI571 represents a breakthrough in GIST treatment, offering significant clinical benefits.
  • This targeted therapy approach, inhibiting a specific activating mutation, serves as a paradigm for other solid tumors.
  • Molecularly targeted therapies are crucial for managing challenging malignancies like GISTs.